PDCD1 and neoplasm: Blocking the CD28-B7 co-stimulatory pathway suppresses the proliferation and activation of tumor-specific CD8+ T cells, and reduces the response to Anti-PD-1/PD-L1 therapy (Hui et al., 2017).